RxDoctor Payments Data

Ryan Harris, MD

Family Medicine · Paragould, ARNPI 1548611049

Payments from drug & device makers

$1,591in general payments, 2019–2025

Across 100 payments — averaging $15.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$291
  • Amgen$212
  • Novo Nordisk$178
  • Lilly USA, LLC$170
  • Mylan Specialty L.p.$163
  • AbbVie$104
  • plus $474 from 18 others

What the payments were for

  • Food & beverage$1,58099%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,591 in reported general payments places this provider in the 65th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$256,767
Medicare patients
478
Services billed
18,071

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban121$100,632
MounjaroTirzepatide76$79,586
OzempicSemaglutide50$44,981
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog29$34,807
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$32,398
FarxigaDapagliflozin Propanediol43$29,993
XareltoRivaroxaban30$26,284
Tresiba Flextouch U-200Insulin Degludec21$21,542
VraylarCariprazine Hcl11$17,754
JanuviaSitagliptin Phosphate23$17,287
MyrbetriqMirabegron14$12,996
JardianceEmpagliflozin21$12,145
EntrestoSacubitril/Valsartan13$11,366
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$9,327
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen236$8,943

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$27$100,632121 claims
Lilly USA, LLCMounjaro$170$79,58676 claims
Novo NordiskOzempic$178$44,98150 claims
AstraZenecaFarxiga, Breztri Aerosphere$26$39,32057 claims
GSKTrelegy Ellipta$64$32,39843 claims
Johnson & JohnsonXarelto$11$26,28430 claims
Boehringer IngelheimJardiance, Stiolto Respimat$29$17,79633 claims
AbbVieVraylar$104$17,75411 claims
Astellas Pharma US IncMyrbetriq$37$12,99614 claims
NovartisEntresto$18$11,36613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Paragould

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →